Radiation enhancement by biochemical modulation and 5-fluorouracil

Jason A. Koutcher, Alan A. Alfieri, Howard Thaler, Cornelia Matei, Daniel S. Martin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To evaluate the effects of biochemical modulation by N- (phosphonacetyl)-L-aspartate (PALA), 6-methylmercaptopurine riboside (MMPR), and 6-aminonicotinamide (6AN), (PALA + MMPR + 6AN is referred to as PMA) on tumor radiosensitivity, and evaluate the efficacy of the addition of 5-PU to the PMA + XRT regimen for enhancement of tumor response to radiation without exceeding normal tissue tolerance. Methods and Materials: A first generation transplant of the CD8F1 spontaneous murine tumor was studied. 31P nuclear magnetic resonance spectroscopy was used to determine the interval between chemotherapy and radiation based on energy depletion. PMA was administered three times with fractionated XRT (15 Gy x 3 = 45 Gy) on days 1, 10, or 11, and 21. The addition of 5-fluorouracil (5-FU) at maximum tolerated doses was evaluated and intergroup comparisons were made for tumor growth delay, local control, and disproportionate normal tissue damage. Results: The combination of 5-FU + XRT induced a tumor doubling time of 75.4 days (67.4-84.4) (p < 0.0001 compared to XRT), validating that in this tumor model, pretreatment with bolus i.p. 5-FU enhanced XRT. In comparison, mice treated with PMA + XRT had a tumor doubling rime (TDT) > 123.2 days (109.4-138.7), (p < 0.0001 compared to 5-FU + XRT). The addition of 5-FU to PMA + XRT induced a doubling time of > 170.8 days (150.7-193.7) (p = 0.0002 compared to PMA + XRT). The doubling time for the PMA + XRT cohort and the PMA + 5-FU + XRT cohorts are underestimates since some of the tumor bearing mice continue to have a complete regression (CR). The CR rate (measured on day 250) for the PMA + 5- FU + XRT cohort was 31.7% compared to 0% for 5-FU + XRT and 10% for PMA + XRT (p < 0.05). Mortality and local effects induced by radiation in the PMA + XRT group were comparable to the toxicity for the PMA + 5-FU + XRT group indicating that the addition of 5-FU at 75 mg/kg to PMA + XRT was tolerated and induced both greater CR and tumor doubling times than XRT alone. 5-FU (150 mg/kg) + XRT, or PMA + XRT. Conclusions: PMA is superior to 5-FU as a radiosensitizer in the schedule studied. The combination of PMA + 5-FU further enhanced XRT without exceeding normal tissue tolerance.

Original languageEnglish (US)
Pages (from-to)1145-1152
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume39
Issue number5
DOIs
StatePublished - Dec 1 1997
Externally publishedYes

Fingerprint

Fluorouracil
tumors
Radiation
modulation
augmentation
radiation
aspartates
regression analysis
6-Aminonicotinamide
Neoplasms
NSC 224131
Methylthioinosine
mortality
magnetic resonance spectroscopy
radiation tolerance
chemotherapy
schedules
toxicity
mice
Maximum Tolerated Dose

Keywords

  • Biochemical modulation
  • Chemotherapy
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Radiation enhancement by biochemical modulation and 5-fluorouracil. / Koutcher, Jason A.; Alfieri, Alan A.; Thaler, Howard; Matei, Cornelia; Martin, Daniel S.

In: International Journal of Radiation Oncology Biology Physics, Vol. 39, No. 5, 01.12.1997, p. 1145-1152.

Research output: Contribution to journalArticle

Koutcher, Jason A. ; Alfieri, Alan A. ; Thaler, Howard ; Matei, Cornelia ; Martin, Daniel S. / Radiation enhancement by biochemical modulation and 5-fluorouracil. In: International Journal of Radiation Oncology Biology Physics. 1997 ; Vol. 39, No. 5. pp. 1145-1152.
@article{c34d45843d46443ebeefea040f54802c,
title = "Radiation enhancement by biochemical modulation and 5-fluorouracil",
abstract = "Purpose: To evaluate the effects of biochemical modulation by N- (phosphonacetyl)-L-aspartate (PALA), 6-methylmercaptopurine riboside (MMPR), and 6-aminonicotinamide (6AN), (PALA + MMPR + 6AN is referred to as PMA) on tumor radiosensitivity, and evaluate the efficacy of the addition of 5-PU to the PMA + XRT regimen for enhancement of tumor response to radiation without exceeding normal tissue tolerance. Methods and Materials: A first generation transplant of the CD8F1 spontaneous murine tumor was studied. 31P nuclear magnetic resonance spectroscopy was used to determine the interval between chemotherapy and radiation based on energy depletion. PMA was administered three times with fractionated XRT (15 Gy x 3 = 45 Gy) on days 1, 10, or 11, and 21. The addition of 5-fluorouracil (5-FU) at maximum tolerated doses was evaluated and intergroup comparisons were made for tumor growth delay, local control, and disproportionate normal tissue damage. Results: The combination of 5-FU + XRT induced a tumor doubling time of 75.4 days (67.4-84.4) (p < 0.0001 compared to XRT), validating that in this tumor model, pretreatment with bolus i.p. 5-FU enhanced XRT. In comparison, mice treated with PMA + XRT had a tumor doubling rime (TDT) > 123.2 days (109.4-138.7), (p < 0.0001 compared to 5-FU + XRT). The addition of 5-FU to PMA + XRT induced a doubling time of > 170.8 days (150.7-193.7) (p = 0.0002 compared to PMA + XRT). The doubling time for the PMA + XRT cohort and the PMA + 5-FU + XRT cohorts are underestimates since some of the tumor bearing mice continue to have a complete regression (CR). The CR rate (measured on day 250) for the PMA + 5- FU + XRT cohort was 31.7{\%} compared to 0{\%} for 5-FU + XRT and 10{\%} for PMA + XRT (p < 0.05). Mortality and local effects induced by radiation in the PMA + XRT group were comparable to the toxicity for the PMA + 5-FU + XRT group indicating that the addition of 5-FU at 75 mg/kg to PMA + XRT was tolerated and induced both greater CR and tumor doubling times than XRT alone. 5-FU (150 mg/kg) + XRT, or PMA + XRT. Conclusions: PMA is superior to 5-FU as a radiosensitizer in the schedule studied. The combination of PMA + 5-FU further enhanced XRT without exceeding normal tissue tolerance.",
keywords = "Biochemical modulation, Chemotherapy, Radiation",
author = "Koutcher, {Jason A.} and Alfieri, {Alan A.} and Howard Thaler and Cornelia Matei and Martin, {Daniel S.}",
year = "1997",
month = "12",
day = "1",
doi = "10.1016/S0360-3016(97)00505-1",
language = "English (US)",
volume = "39",
pages = "1145--1152",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Radiation enhancement by biochemical modulation and 5-fluorouracil

AU - Koutcher, Jason A.

AU - Alfieri, Alan A.

AU - Thaler, Howard

AU - Matei, Cornelia

AU - Martin, Daniel S.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Purpose: To evaluate the effects of biochemical modulation by N- (phosphonacetyl)-L-aspartate (PALA), 6-methylmercaptopurine riboside (MMPR), and 6-aminonicotinamide (6AN), (PALA + MMPR + 6AN is referred to as PMA) on tumor radiosensitivity, and evaluate the efficacy of the addition of 5-PU to the PMA + XRT regimen for enhancement of tumor response to radiation without exceeding normal tissue tolerance. Methods and Materials: A first generation transplant of the CD8F1 spontaneous murine tumor was studied. 31P nuclear magnetic resonance spectroscopy was used to determine the interval between chemotherapy and radiation based on energy depletion. PMA was administered three times with fractionated XRT (15 Gy x 3 = 45 Gy) on days 1, 10, or 11, and 21. The addition of 5-fluorouracil (5-FU) at maximum tolerated doses was evaluated and intergroup comparisons were made for tumor growth delay, local control, and disproportionate normal tissue damage. Results: The combination of 5-FU + XRT induced a tumor doubling time of 75.4 days (67.4-84.4) (p < 0.0001 compared to XRT), validating that in this tumor model, pretreatment with bolus i.p. 5-FU enhanced XRT. In comparison, mice treated with PMA + XRT had a tumor doubling rime (TDT) > 123.2 days (109.4-138.7), (p < 0.0001 compared to 5-FU + XRT). The addition of 5-FU to PMA + XRT induced a doubling time of > 170.8 days (150.7-193.7) (p = 0.0002 compared to PMA + XRT). The doubling time for the PMA + XRT cohort and the PMA + 5-FU + XRT cohorts are underestimates since some of the tumor bearing mice continue to have a complete regression (CR). The CR rate (measured on day 250) for the PMA + 5- FU + XRT cohort was 31.7% compared to 0% for 5-FU + XRT and 10% for PMA + XRT (p < 0.05). Mortality and local effects induced by radiation in the PMA + XRT group were comparable to the toxicity for the PMA + 5-FU + XRT group indicating that the addition of 5-FU at 75 mg/kg to PMA + XRT was tolerated and induced both greater CR and tumor doubling times than XRT alone. 5-FU (150 mg/kg) + XRT, or PMA + XRT. Conclusions: PMA is superior to 5-FU as a radiosensitizer in the schedule studied. The combination of PMA + 5-FU further enhanced XRT without exceeding normal tissue tolerance.

AB - Purpose: To evaluate the effects of biochemical modulation by N- (phosphonacetyl)-L-aspartate (PALA), 6-methylmercaptopurine riboside (MMPR), and 6-aminonicotinamide (6AN), (PALA + MMPR + 6AN is referred to as PMA) on tumor radiosensitivity, and evaluate the efficacy of the addition of 5-PU to the PMA + XRT regimen for enhancement of tumor response to radiation without exceeding normal tissue tolerance. Methods and Materials: A first generation transplant of the CD8F1 spontaneous murine tumor was studied. 31P nuclear magnetic resonance spectroscopy was used to determine the interval between chemotherapy and radiation based on energy depletion. PMA was administered three times with fractionated XRT (15 Gy x 3 = 45 Gy) on days 1, 10, or 11, and 21. The addition of 5-fluorouracil (5-FU) at maximum tolerated doses was evaluated and intergroup comparisons were made for tumor growth delay, local control, and disproportionate normal tissue damage. Results: The combination of 5-FU + XRT induced a tumor doubling time of 75.4 days (67.4-84.4) (p < 0.0001 compared to XRT), validating that in this tumor model, pretreatment with bolus i.p. 5-FU enhanced XRT. In comparison, mice treated with PMA + XRT had a tumor doubling rime (TDT) > 123.2 days (109.4-138.7), (p < 0.0001 compared to 5-FU + XRT). The addition of 5-FU to PMA + XRT induced a doubling time of > 170.8 days (150.7-193.7) (p = 0.0002 compared to PMA + XRT). The doubling time for the PMA + XRT cohort and the PMA + 5-FU + XRT cohorts are underestimates since some of the tumor bearing mice continue to have a complete regression (CR). The CR rate (measured on day 250) for the PMA + 5- FU + XRT cohort was 31.7% compared to 0% for 5-FU + XRT and 10% for PMA + XRT (p < 0.05). Mortality and local effects induced by radiation in the PMA + XRT group were comparable to the toxicity for the PMA + 5-FU + XRT group indicating that the addition of 5-FU at 75 mg/kg to PMA + XRT was tolerated and induced both greater CR and tumor doubling times than XRT alone. 5-FU (150 mg/kg) + XRT, or PMA + XRT. Conclusions: PMA is superior to 5-FU as a radiosensitizer in the schedule studied. The combination of PMA + 5-FU further enhanced XRT without exceeding normal tissue tolerance.

KW - Biochemical modulation

KW - Chemotherapy

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0030658007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030658007&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(97)00505-1

DO - 10.1016/S0360-3016(97)00505-1

M3 - Article

C2 - 9392557

AN - SCOPUS:0030658007

VL - 39

SP - 1145

EP - 1152

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -